The Company incurred operating expenses of
The Company incurred operating expenses of
Reata began trading on the
“The successful execution of our initial public offering this past quarter has enhanced our company’s financial position and will allow us to continue our mission of developing novel therapeutics for patients with life threatening diseases and few, or no, approved therapies,” said
Product Development Highlights
The Company’s strategy is to focus on rare and life threatening diseases with few or no approved therapies. Reata surveys for clinical benefit in patients with these severe diseases by running multiple Phase 2 proof-of-concept studies in parallel. Reata’s goal is to build and maintain a broad pipeline of clinical candidates and development opportunities.
Bardoxolone Methyl in Pulmonary Hypertension
Reata is conducting clinical programs of the Company’s lead drug, bardoxolone methyl, in patients with pulmonary hypertension that is caused by constriction of the pulmonary artery (“PAH”). Despite treatment with vasodilator therapy, PAH is a fatal disease with a five-year survival rate of only 68 percent of patients. PAH patients experience mitochondrial dysfunction, increased activation of NF-κB and related inflammatory pathways involved in ROS signaling, cellular proliferation, and fibrosis. Bardoxolone methyl, through the combined effect of Nrf2 activation and NF-κB suppression, has the potential to restore mitochondrial function, reduce oxidative stress, resolve inflammation and reduce the production of enzymes related to fibrosis and tissue remodeling.
Reata presented the initial results of the Company’s PAH clinical study, called LARIAT, at the CHEST world congress during
Because bardoxolone methyl was active in patients with CTD-PAH (a fibrotic disease), Reata believes that bardoxolone methyl may be effective in patients with pulmonary hypertension (“PH”) that is caused by fibrosis of the lung (rather than the pulmonary artery as in PAH). These forms of PH are caused by interstitial lung diseases (“ILD”) including idiopathic pulmonary fibrosis and sarcoidosis. Each one of these is a fatal disease with no approved therapy for their PH-ILD. During the last year, the Company initiated four Phase 2 programs testing bardoxolone methyl’s effectiveness in PH from four subtypes of ILD. The Company expects to have data from these trials during the second half of 2017.
Omaveloxolone in Rare Neuromuscular Diseases and Immuno-Oncology
During the last year, Reata advanced the clinical development of omaveloxolone, a close analog of bardoxolone methyl that has improved blood-brain barrier penetration. The Company believes that it may benefit patients with various types of neuromuscular diseases because impaired mitochondrial function and chronic inflammation have been shown to be key features of many of these diseases. The Company is initially targeting two rare genetic diseases: one is primarily neural, Friedrich’s ataxia (“FA”), and one is primarily muscular, mitochondrial myopathy (“MM”). These are also severe and often fatal diseases with no approved therapy. Reata is conducting robust, double-blind, placebo-controlled, international Phase 2 studies in each disease. The FA study is known as MOXIe, and the MM study is known as MOTOR. Initial data from MOXIe and MOTOR are expected in the first half of 2017.
The Company is also conducting an open-label Phase 1b/2 trial, known as REVEAL, to evaluate the safety, pharmacodynamics, and efficacy of omaveloxolone in combination with existing immunotherapies for the treatment of metastatic melanoma. The Company is using omaveloxolone in combination with checkpoint inhibitors to restore an immune response against the tumor in the presence of so called myeloid derived suppressor cells (“MDSCs”). MDSCs mask the tumor from the immune system by production of mitochondrial ROS. Through this approach, Reata hopes to significantly increase the proportion of patients that respond to immunotherapy. Data from REVEAL are expected during the second half of 2017.
In addition to the Company’s current clinical programs, Reata is advancing two new classes of drugs that address important molecular pathways involved in mitochondrial function and inflammation. The Company is pursuing preclinical development of neuroprotective Hsp90 inhibitors, including RTA 901, for the potential treatment of ALS, diabetic neuropathy, spinocerebellar ataxia, and spinal bulbar muscular atrophy, and RORγT inhibitors for the potential treatment of a variety of autoimmune and inflammatory conditions.
About Reata Pharmaceuticals, Inc.
This press release includes certain disclosures which contain “forward-looking statements,” including, without limitation, statements regarding the success, cost and timing of our product development activities and clinical trials, our plans to research, develop and commercialize our product candidates, and our ability to obtain and retain regulatory approval of our product candidates. You can identify forward-looking statements because they contain words such as “believes,” “will,” “may,” “aims,” “plans” and “expects.” Forward-looking statements are based on Reata’s current expectations and assumptions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that may differ materially from those contemplated by the forward-looking statements, which are neither statements of historical fact nor guarantees or assurances of future performance. Important factors that could cause actual results to differ materially from those in the forward-looking statements are set forth in Reata’s filings with the
|Three Months ended||Six Months ended|
|June 30,||June 30,|
|Unaudited Consolidated Statements of Operations||(in thousands, except share and per share data)|
|License and milestone||$||12,365||$||12,365||$||24,730||$||25,294|
|Total collaboration revenue||12,366||12,365||24,804||25,294|
|Research and development||9,075||9,688||18,381||18,266|
|General and administrative||4,537||3,369||7,744||6,223|
|Depreciation and amortization||179||529||367||1,062|
|Total other income||28||8||51||16|
|Loss before (benefit) provision for taxes on income||(1,397||)||(1,213||)||(1,637||)||(241||)|
|(Benefit) provision for taxes on income||(461||)||482||(443||)||96|
|Net loss per share—basic||$||(0.05||)||$||(0.11||)||$||(0.07||)||$||(0.02||)|
|Net loss per share—diluted||$||(0.05||)||$||(0.11||)||$||(0.07||)||$||(0.02||)|
|Weighted-average number of common shares used in net loss per share basic||18,562,302||15,973,020||17,274,574||15,970,022|
|Weighted-average number of common shares used in net loss per share diluted||18,562,302||15,973,020||17,274,574||15,970,022|
|As of||As of|
|June 30, 2016||December 31, 2015|
|Condensed Consolidated Balance Sheet Data|
|Cash and cash equivalents||$||92,365||$||42,008|
|Federal income tax receivable||17,170||31,926|
|Deferred revenue (including current portion)||316,042||340,771|
|Total stockholders' equity||$||(212,144||)||$||(273,156||)|
Reata Pharmaceuticals, Inc.(972) 865-2219 email@example.com http://news.reatapharma.com Investor Relations: The Trout Group Lee M. Stern, CFA (646) 378-2922 IR@reatapharma.com